Table 2 The 25 IPA-pathways most significantly enriched for BMI-associated gene-specific transcripts in the SHIP-TREND/KORA F4 meta-analysis
Defined gene expression signatures with assigned canonical IPA-pathways | FDR for genes with BMI-associated mRNA levels (all genes/ positively associated/ negatively associated) | Number of genes with BMI-associated mRNA levels (all genes/ positively associated/ negatively associated) | FDR from permutation analysis |
|---|---|---|---|
Erythrocyte-Reticulocyte Ratio Shift | |||
EIF2 signaling | 6.8 × 10-8/ 6.3 × 10-14/ 5.8 × 10-1 | 70/ 46/ 24 | 0.0002 |
Mitochondrial dysfunction | 1.0 × 10-5/ 3.6 × 10-8/ 3.2 × 10-1 | 58/ 34/ 24 | 0.0002 |
Regulation of eIF4 and p70S6K signaling | 1.7 × 10-5/ 4.5 × 10-6/ 1.3 × 10-1 | 55/ 29/ 26 | 0.0002 |
mTOR signaling | 5.4 × 10-4/ 1.1 × 10-2/ 6.9 × 10-2 | 60/ 26/ 34 | 0.0059 |
Oxidative phosphorylation | 7.9 × 10-4/ 4.9 × 10-8/ N. A. | 34/ 25/ 9 | 0.0002 |
Heme biosynthesis II | 1.9 × 10-3/ 4.5 × 10-6/ N. A. | 7/ 7/ 0 | 0.0002 |
Attenuated Insulin Signaling | |||
PI3K/AKT signaling | 1.7 × 10-5/ 3.6 × 10-1/ 6.9 × 10-4 | 49/ 15/ 34 | 0.0002 |
Insulin receptor signaling | 6.5 × 10-5/ 8.6 × 10-1/ 5.8 × 10-4 | 49/ 13/ 36 | 0.0002 |
Hypoxia signaling in the cardiovascular system | 6.5 × 10-5/ 4.5 × 10-1/ 6.9 × 10-4 | 30/ 9/ 21 | 0.0002 |
Chronic myeloid leukemia signaling | 1.5 × 10-4/ 4.5 × 10-1/ 1.7 × 10-3 | 38/ 12/ 26 | 0.0002 |
Production of NO and ROS in macrophages | 1.5 × 10-4/ N. A./ 4.3 × 10-6 | 62/ 9/ 53 | 0.0002 |
Pancreatic adenocarcinoma signaling | 1.5 × 10-4/ 7.6 × 10-1/ 7.4 × 10-4 | 42/ 12/ 30 | 0.0134 |
ILK signaling | 1.9 × 10-4/ 8.8 × 10-1/ 5.8 × 10-4 | 62/ 15/ 47 | 0.0002 |
AMPK signaling | 3.1 × 10-4/ 7.7 × 10-1/ 1.6 × 10-3 | 48/ 14/ 34 | 0.0026 |
JAK-STAT signaling | 3.1 × 10-4/ 8.8 × 10-1/ 6.9 × 10-4 | 31/ 7/ 24 | 0.0154 |
Renal cell carcinoma signaling | 3.1 × 10-4/ 6.8 × 10-1/ 2.1 × 10-3 | 30/ 9/ 21 | 0.0170 |
Ceramide signaling | 3.8 × 10-4/ 9.2 × 10-1/ 6.9 × 10-4 | 33/ 7/ 26 | 0.0026 |
mTOR signaling | 5.4 × 10-4/ 1.1 × 10-2/ 6.9 × 10-2 | 60/ 26/ 34 | 0.0059 |
CTLA4 signaling in cytotoxic T lymphocytes | 6.2 × 10-4/ 5.0 × 10-2/ 3.8 × 10-2 | 33/ 14/ 19 | 0.0002 |
B cell receptor signaling | 7.4 × 10-4/ 9.2 × 10-1/ 5.8 × 10-4 | 56/ 12/ 44 | 0.0002 |
Prostate cancer signaling | 7.9 × 10-4/ 9.2 × 10-1/ 8.5 × 10-4 | 32/ 7/ 25 | 0.0002 |
Glioma signaling | 7.9 × 10-4/ 4.5 × 10-1/ 7.6 × 10-3 | 36/ 12/ 24 | 0.0085 |
Non-small cell lung cancer signaling | 1.4 × 10-3/ 9.2 × 10-1/ 1.5 × 10-3 | 27/ 6/ 21 | 0.0002 |
Cyclins and cell cycle regulation | 2.0 × 10-3/ 1.9 × 10-1/ 4.1 × 10-2 | 30/ 12/ 18 | 0.0002 |
PDGF signaling | 2.0 × 10-3/ 9.0 × 10-1/ 1.7 × 10-3 | 30/ 7/ 23 | 0.1620 |
Reduced Protection against Oxidative Stress | |||
NRF2-mediated oxidative stress response | 3.5 × 10-5/ 8.7 × 10-1/ 8.5 × 10-4 | 60/ 17/ 43 | 0.0489 |